Contents
Current Cancer Drug Targets, Volume 16 - Number 4
Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
, 16(4): 288 - 304Zhipeng Zou, Juan Chen, Jun Yang and Xiaochun Bai
DOI: 10.2174/1568009616666151113120830
A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphom a Molecular Subtypes: A Cell of Origin-Driven Review
, 16(4): 305 - 322Jose D. Sandoval-Sus, Julio Chavez and Samir Dalia
DOI: 10.2174/1568009615666151030102539
New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia
, 16(4): 323 - 345Rui Huang, Qian Kang, Huimin Liu and Yuhua Li
DOI: 10.2174/1568009615666150921141004
Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
, 16(4): 346 - 356Xue-Qing Hu, Yang Sun, Eric Lau, Ming Zhao and Shi-Bing Su
DOI: 10.2174/1568009616666151207105851
Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
, 16(4): 357 - 372Niladri Shekhar Dey, Biswajit Mukherjee, Ruma Maji and Bhabani Sankar Satapathy
DOI: 10.2174/1568009616666151106120606
Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
, 16(4): 373 - 385Alessio Papi, Marzia Govoni, Carmen Ciavarella, Enzo Spisni, Marina Orlandi and Fulvia Farabegoli
DOI: 10.2174/1568009615666150817120931
Webmaster Contact: info@benthamscience.org